Chemistry:PF-06647020
 | It has been suggested that this page be merged into Cofetuzumab pelidotin. (Discuss) Proposed since October 2018. |
PF-06647020 is an experimental antibody-drug conjugate in development for the treatment of cancer. It was created by Stemcentrx and is being developed by Pfizer. The drug is an anti-PTK7 monoclonal antibody linked to Auristatin-0101, an auristatin microtubule inhibitor.[1][2]
Antibody-drug conjugates use a monoclonal antibody that binds to tumors cells linked to a cytotoxic drug. This allows the drug to selectively target the cells that the antibody binds to.
PTK7 is expressed by many tumors, including ovarian cancer, breast cancer, and non-small cell lung cancer.[3] Early clinical trial results show a 50% response rate in patients with triple negative breast cancer and an almost complete response in ovarian tumors resistant to platinum-based chemotherapies.[4]
References
- ↑ "PF-06647020 Archives – ADC Review ADC Review". Adcreview.com. http://adcreview.com/tag/pf-06647020/. Retrieved 2017-05-22.
- ↑ "Pfizer Oncology: ADC Development Overview (2016) – ADC Review ADC Review". Adcreview.com. http://adcreview.com/pfizer-adc-development-overview-2016/. Retrieved 2017-05-22.
- ↑ http://www.pfizer.com/files/news/esmo/ESMO2016_Oncology_Technologies_Fact_Sheet_ADC.pdf
- ↑ Patrick, Margaret (2016-06-28). "Why AbbVie Expects PTK7 to Enhance Its Oncology Capabilities". Market Realist. http://marketrealist.com/2016/06/abbvie-expects-ptk7-targeted-drug-enhance-oncology-capabilities/. Retrieved 2017-05-22.
 |
